{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014663","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.572030+00:00","generated_at":"2026-05-30T04:17:57.404101+00:00","sec_items":["2.02","5.07","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Phibro Q1 net sales $260.4M (+13% YoY), net income $7.0M vs loss; updates FY25 guidance","bullets":["Net sales $260.4M (+13% YoY); net income $7.0M vs net loss $8.0M; diluted EPS $0.17 vs -$0.20.","Adjusted EBITDA $30.7M, +64% YoY; adjusted diluted EPS $0.35 vs $0.14 prior year.","Updated FY2025 guidance: net sales $1.05B-$1.10B; Adjusted EBITDA $124M-$132M (15% growth).","Discontinued atopic dermatitis project; expects ~$200M sales from Zoetis MFA portfolio in FY2025.","Gross margin improved 280 bps to 32.1%; interest expense up $3.1M due to refinancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014663","json":"https://secwatch.observer/filing/0001558370-24-014663.json","markdown":"https://secwatch.observer/filing/0001558370-24-014663.md","text":"https://secwatch.observer/filing/0001558370-24-014663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024014663/0001558370-24-014663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024014663/pahc-20241105x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:17:57.404101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}